The pharmaceutical company Gilead has announced that its new pre-exposure prophylactic (PrEP) injectable medication has passed a Phase III clinical trial demonstrating its safety and effectiveness ...
The FDA has approved lenacapvir, a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications. The drug, which will be sold under the brand ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback